- Arimoclomol maleate
-
- $39.00 / 5mg
-
2026-02-01
- CAS:289893-26-1
- Min. Order:
- Purity: 99.90%
- Supply Ability: 10g
- Arimoclomol maleate
-
- $39.00 / 5mg
-
2026-02-01
- CAS:289893-26-1
- Min. Order:
- Purity: 99.90%
- Supply Ability: 10g
|
| | AriMocloMol Maleic Acid Basic information |
| | AriMocloMol Maleic Acid Chemical Properties |
| Melting point | >131°C (dec.) | | storage temp. | Amber Vial, -20°C Freezer, Under inert atmosphere | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | Solid | | color | White to Off-White | | Water Solubility | H2O: 2mg/mL, clear | | InChIKey | OHUSJUJCPWMZKR-FEGZNKODSA-N | | SMILES | Cl/C(C1=CC=C[N+]([O-])=C1)=N\OC[C@@H](CN2CCCCC2)O.O=C(O)/C=C\C(O)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | AriMocloMol Maleic Acid Usage And Synthesis |
| Uses | AriMocloMol Maleic Acid is a orally administered drug used to treat amyotrophic lateral sclerosis and was later discovered to be a potential insulin resistance treatment and diabetic complications. | | Biological Activity | Arimoclomol is an orally available, CNS-penetrant coinducer of he at shock proteins (HSPs), notably HSP70, th at exhibits in vivo efficay in disease models of diabetes, Gaucher disease (GD), sporadic inclusion body myositis (sIBM), and neurological disorders, including amyotrophic lateral sclerosis (ALS) and Niemann-Pick disease type C1 (NPC1). Note: arimoclomol maleate and citrate salt forms are known as BRX-220 and BRX-345, respectively. | | in vivo | Arimoclomol (BRX-220; 20 mg/kg; orally administered for 5 d) has a protective effect against cholecystokinin-octapeptide (CCK)-induced acute pancreatitis[1]. | Animal Model: | Male Wistar rats weighing 240 to 270 g[1] | | Dosage: | 20 mg/kg | | Administration: | Administered intragastrically, for 5 days | | Result: | Had a protective effect against CCK-induced acute pancreatitis. |
| | IC 50 | HSP |
| | AriMocloMol Maleic Acid Preparation Products And Raw materials |
|